Sionna Therapeutics (NASDAQ:SION) Major Shareholder Sells $10,000,000.00 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) major shareholder Tpg Gp A, Llc sold 250,000 shares of the business’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the transaction, the insider owned 6,494,962 shares of the company’s stock, valued at $259,798,480. This represents a 3.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Sionna Therapeutics Stock Down 2.9%

Shares of NASDAQ SION opened at $42.13 on Thursday. The firm’s 50-day moving average price is $41.42 and its 200-day moving average price is $31.95. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $45.00. The company has a market cap of $1.88 billion and a PE ratio of -8.65.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Institutional Trading of Sionna Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Viking Global Investors LP raised its holdings in shares of Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock valued at $55,436,000 after purchasing an additional 242,427 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Sionna Therapeutics by 2.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after purchasing an additional 51,589 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Sionna Therapeutics by 81.4% during the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after buying an additional 512,803 shares during the last quarter. Braidwell LP acquired a new stake in Sionna Therapeutics during the 2nd quarter worth about $18,770,000. Finally, Aberdeen Group plc lifted its holdings in shares of Sionna Therapeutics by 27.4% during the second quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock worth $16,492,000 after purchasing an additional 204,583 shares during the period.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. BTIG Research reissued a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Lifesci Capital began coverage on shares of Sionna Therapeutics in a research report on Tuesday, December 23rd. They set an “outperform” rating and a $60.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Sionna Therapeutics has an average rating of “Moderate Buy” and an average price target of $45.43.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.